Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02696564 · ClinicalTrials.gov registry record · Phase 4

Losartan Effects on Emphysema Progression

A Phase 4 study of Emphysema, sponsored by JHSPH Center for Clinical Trials.

Completed
Registry status
Phase 4
Development phase
220
Enrollment target
20
Study locations

NCT02696564: Completed Phase 4 study of Emphysema, sponsored by JHSPH Center for Clinical Trials.

NCT02696564 is a Phase 4 study of Emphysema that has completed, run by JHSPH Center for Clinical Trials. The registered enrollment target is 220 participants, below the 3,795-participant average among 25 other Emphysema trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02696564, a Phase 4 study of Emphysema, has completed, sponsored by JHSPH Center for Clinical Trials.

COMPLETED
Registry status
Phase 4
Development phase
220 participants
Enrollment target
20
Study locations

Study Summary

A randomized, parallel, placebo controlled trial to evaluate the effect of 100mg/day losartan on the progression of emphysema as measured by quantitative HRCT compared to placebo .

Primary Outcome

change in percentage of voxels with density less than -950 Hounsfield Units

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Losartan

Study Locations (20)

Illinois

  • University of Illinois at Chicago - Chicago
  • Northwestern University - Chicago
  • Rush University Medical Center - Chicago
  • University of Chicago Hospitals - Chicago

California

  • University of California at San Diego - San Diego
  • University of California at San Francisco - San Francisco

Florida

  • University of Florida College of Medicine - Jacksonville
  • University of South Florida - Tampa

Missouri

  • St. Louis University School of Medicine - St Louis
  • St. Louis Asthma Clinical Research Center - Washington University School of Medicine - St Louis

New York

  • New York University School of Medicine - New York
  • Weill Cornell Medicine - New York

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • University of Arizona - Tucson

Colorado

  • National Jewish Medical and Research Center - Denver

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2017-05-23
Est. Completion 2021-06-30
Phase Phase 4
JHSPH Center for Clinical Trials

12 total trials

What the finished NCT02696564 record still lists

NCT02696564 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 3,795-participant average among 25 other Emphysema trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Emphysema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02696564 names 20 study sites across 13 states, led by Illinois, California, Florida.

Frequently Asked Questions

What is clinical trial NCT02696564 about?

NCT02696564 is a clinical study titled "Losartan Effects on Emphysema Progression". A randomized, parallel, placebo controlled trial to evaluate the effect of 100mg/day losartan on the progression of emphysema as measured by quantitative HRCT compared to placebo .

What is the current status of trial NCT02696564?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 220 participants. The study started on 2017-05-23. Estimated completion is 2021-06-30.

What conditions does trial NCT02696564 study?

This clinical trial studies the following conditions: Emphysema.

What interventions are being tested in trial NCT02696564?

The interventions under investigation include: Placebo (DRUG), Losartan (DRUG).

Who is sponsoring clinical trial NCT02696564?

This trial is sponsored by JHSPH Center for Clinical Trials, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02696564 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Emphysema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02696564's enrollment target sits among peer trials

220 10th of 25 higher than 16 of 25 other Emphysema trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Emphysema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02696564, the US trial registry maintained by the National Library of Medicine. NCT02696564 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.